

JAGADISHWAR

**PHARMACEUTICAL
WORKS LIMITED**

CIN - L24232AS1987PLC002803

Regd. Off.: 205, Haribol Roy Market, 2nd Floor, A.T.Road, Guwahati -781001

Corp. Off.: 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E_mail ID: jpwltd@yahoo.com

Phone No.: +91 7890586947

Date: November 14, 2017

To,
Head- Listing & Compliance
Metropolitan Stock Exchange of India Ltd. (MSEI),
4th Floor, Vibgyor Towers, Plot No. C 62,
G Block, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 098.

Sub: Submission of Un-Audited Financial Results with Limited Review Report as per Regulation 33 (3)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the Quarter ended 30th September, 2017.

Dear Sir / Madam,

Please find enclosed herewith the IND AS- Un-audited Financial Results with Limited Review Report as per Regulation 33(3)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the Quarter ended 30th September, 2017.

You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For Jagadishwar Pharmaceutical Works Limited



Swapan Sarkar
Director
DIN : 05149442

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd. Office : 205, Haribol Roy Market, A.T.Road

2nd Floor, Near Saraf Building, Guwahati - 781 001

Email: jpwlttd@yahoo.com, Website: jagadishwarpharma.com, Tel.: +917890586947

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2017

(Rs. In Lacs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30-09-2017	30-06-2017	30-09-2016	30-09-2017	30-09-2016	31-03-2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I Income from Operations						
(a) Net sales/income from operation (Net of excise duty)	-	-	37.55	-	42.05	59.80
(b) Other operating income	-	-	-	-	-	-
Total income from operations (net)	-	-	37.55	-	42.05	59.80
II Expenses						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchase of stock-in-trade	-	17.68	38.00	17.68	48.00	367.46
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	(17.68)	0.60	(17.68)	(1.40)	(289.60)
(d) Employee benefits expense	1.70	1.70	2.02	3.41	4.03	8.09
(e) Depreciation and amortisation expense	-	-	-	-	-	1.57
(f) Finance Cost	-	-	-	-	-	-
(g) Other expenses	0.98	2.56	1.72	3.53	5.05	11.71
Total expenses	2.68	4.26	42.34	6.94	55.68	99.23
III Profit (Loss) before exceptional Items and extraordinary items and tax (I-II)	(2.68)	(4.26)	(4.79)	(6.94)	(13.63)	(39.43)
IV Other income	-	8.97	11.34	8.98	22.89	45.34
V Profit/ (Loss) from ordinary activities before finance costs and exceptional (III(+ /-)IV)	(2.68)	4.71	6.55	2.04	9.26	5.91
VI Extra Ordinary Items	-	-	-	-	-	-
VII Net Profit/(Loss) before tax (V(+/-)VI)	(2.68)	4.71	6.55	2.04	9.26	5.91
VIII Tax expense :						
(1) Current Tax	-	-	-	-	3.36	-
(2) Deferred Tax	-	-	-	-	-	-
Total Tax Expenses	-	-	-	-	3.36	-
IX Net profit /(Loss) for the period from continuing operations (VII-VIII)	(2.68)	4.71	6.55	2.04	5.90	5.91
X Profit/(Loss) for the period from discontinuing operations	-	-	-	-	-	-
XI Tax expense of discontinuing operations	-	-	-	-	-	-
XII Profit/(Loss) for the period from discontinuing operations (after tax)	-	-	-	-	-	-
XIII Profit (Loss) for the period (IX + XII)	(2.68)	4.71	6.55	2.04	5.90	5.91
XIV Other Comprehensive Income	-	-	-	-	-	-
XV Total Comprehensive Income	-	-	-	-	-	-
XVI Paid up equity share capital (Face Value of Rs.10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02
XVII Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	10.36
XVIII Earnings Per Share (EPS)						
(a) Basic	-	-	-	-	-	-
(b) Diluted	-	-	-	-	-	-

Notes:


- The above results are in compliance with Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. The results for the previous periods have been restated as per Ind AS. The standalone financial results of the Company for the quarter and half year ended 30th September, 2017 have been reviewed by the Audit Committee at their meeting held on 14th November, 2017 and have been approved by the Board of Directors at its meeting held on 14th November, 2017.
- Reconciliation of Net Profit & Equity as previously reported under India GAAP (IGAAP) and Ind-AS for the quarters/periods are presented as under:

Particulars	Net Profit Reconciliation			Equity Reconciliation
	Quarter ended 30-09-2016	Period ended 30-09-2016	Year ended 31-03-2017	As at 31-03-2017
Net Profit/Equity as per IGAAP	-	-	-	-
Appreciation/ (Diminution) in value of Investments	-	-	-	-
Reclassification of Net Actuarial (Gain) / Loss on employee defined benefit obligation to other comprehensive income	-	-	-	-
Net Profit/Equity as per Ind-AS	-	-	-	-
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income/Equity as per Ind-AS	-	-	-	-

- The standalone financial results of the Company for the quarter and half year ended 30th September, 2017 have been unaudited by the Statutory Auditors.
- The Statutory Auditors have carried out a "Limited Review" of the above financial results for the quarter/half ended 30th September, 2017.
- Previous period/Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited

Place : Guwahati
Date : 14.11.2017


 Swapan Sarkar
 Managing Director
 (DIN: 05149442)

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd. Office : 205, Haribol Roy Market, A.T.Road
2nd Floor, Near Saraf Building, Guwahati - 781 001

Standalone Statement of Assets and Liabilities

(Rs. In Lacs)

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at (current half year end) (30/09/2017)	As at (Previous year end) (30/09/2016)
A	EQUITY AND LIABILITIES		
1	Shareholder's funds		
	(a) Share capital	2,970.01	2,970.01
	(b) Reserves and surplus	23.92	21.87
	(c) Money received against share warants	-	-
	Sub- total - Shareholder's funds	2,993.93	2,991.88
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	Sub-total-Non-current liabilities	-	-
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c) Other current liabilities	10.70	-
	(d) Short-term provisions	-	-
	Sub-total- Current liabilities	10.70	-
	TOTAL - EQUITY AND LIABILITIES	3,004.63	2,991.88
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	1.39	2.97
	(i) Tangible assets	-	-
	(ii) Intangible assets	-	-
	(iii) Capital Work in Progress	-	-
	(iv) Intangible assets under development	-	-
	(b) Non-current investments	1,251.87	1,669.61
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	11.24	11.98
	(e) Other non-current assets	-	-
	Sub-total-Non-current assets	1,264.50	1,684.56
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	1,140.73	834.84
	(c) Trade receivables	0.01	-
	(d) Cash and cash equivalents	25.99	0.88
	(e) Short-term loans and advances	573.40	471.60
	(f) Other current assets	-	-
	Sub-total-Current assets	1,740.13	1,307.32
	TOTAL - ASSETS	3,004.63	2,991.88

For and on behalf of the Board of
For Jagadishwar Pharmaceutical Works Limited


 Managing Director
 (DIN: 05149442)

Shantimay Majumder & Co.

Chartered Accountants

57, Ramesh Mitra Road

Kolkata – 700 025

E-mail : cashantimoy@gmail.com

Date :

Ref :

LIMITED REVIEW REPORT

To

The Board of Directors,

Jagadishwar Pharmaceutical Works Limited

We have reviewed the unaudited financial results of **Jagadishwar Pharmaceutical Works Limited** (“the Company”), for the quarter ended September 30, 2017 together with the notes thereon (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), which has been initialed by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company’s opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim financial information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to the following matters:

- a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017, and accordingly, the Statement has been prepared by the Company’s Management in compliance with Ind AS.
- b) We were neither engaged to review, nor have we reviewed the comparative figures including reconciliation to the Total Comprehensive Income for the quarter ended on September 30, 2017. As set out in note 5 to the Statement, these figures have been furnished by the Management.

Place : Kolkata

Date : 14th November, 2017

For **Shantimay Majumder & Co.**
Chartered Accountants
Firm Regd. No.-317116E
57, Ramesh Mitra Road, 1st Floor, Kol-25

S. Majumder

S. Majumder

Proprietor & No. 317116E

MAN-APPENDIX (C)

Saantimoy Majumder
(Proprietor)

Membership No : 053264

Firm Regn. No.: 317116E